End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
54.11 CNY | +0.43% | +2.33% | +10.09% |
Jun. 06 | Yuyue Medical Owners Prohibited from Leaving China for Alleged Links to Baiyao Corruption Case | MT |
May. 13 | Yunnan Baiyao's Unit to Conduct Clinical Trials on Prostate Cancer Drug | MT |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.09% | 13.32B | C+ | ||
+45.82% | 765B | C+ | ||
-6.16% | 354B | C+ | ||
+19.86% | 331B | B- | ||
+9.32% | 299B | C+ | ||
+18.87% | 248B | B+ | ||
-0.94% | 219B | A+ | ||
+11.06% | 216B | B- | ||
+5.90% | 164B | C+ | ||
-0.73% | 162B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000538 Stock
- Ratings Yunnan Baiyao Group Co.,Ltd